Mitsubishi UFJ Asset Management Co. Ltd. Sells 3,485 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Mitsubishi UFJ Asset Management Co. Ltd. reduced its holdings in shares of Twist Bioscience Co. (NASDAQ:TWST) by 6.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,219 shares of the company’s stock after selling 3,485 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.08% of Twist Bioscience worth $2,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of TWST. Barclays PLC boosted its holdings in shares of Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after acquiring an additional 104,420 shares during the last quarter. FMR LLC grew its position in Twist Bioscience by 6.0% in the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock worth $9,875,000 after purchasing an additional 12,327 shares during the period. Avanza Fonder AB bought a new stake in Twist Bioscience in the 4th quarter worth approximately $1,059,000. BNP Paribas Financial Markets raised its stake in Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after buying an additional 21,357 shares during the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock valued at $9,301,000 after buying an additional 82,953 shares during the period.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $38.94 on Wednesday. The stock has a market capitalization of $2.32 billion, a PE ratio of -11.52 and a beta of 2.15. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The business has a 50 day simple moving average of $44.76 and a two-hundred day simple moving average of $45.28. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter last year, the business earned ($0.75) earnings per share. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. On average, research analysts predict that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Emily M. Leproust sold 1,726 shares of the firm’s stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $41.68, for a total value of $71,939.68. Following the completion of the sale, the chief executive officer now owns 660,966 shares in the company, valued at approximately $27,549,062.88. This trade represents a 0.26 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Paula Green sold 918 shares of the company’s stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the transaction, the senior vice president now owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,799 shares of company stock worth $1,593,944. Corporate insiders own 3.01% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on TWST. Wolfe Research initiated coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price objective for the company. Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. JPMorgan Chase & Co. upped their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a report on Tuesday, February 4th. Robert W. Baird increased their price target on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. Finally, Barclays set a $58.00 price objective on Twist Bioscience and gave the company an “overweight” rating in a research note on Monday, February 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and an average price target of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.